Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueGross MarginNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Sales

Pharming (PHAR) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for Pharming (PHAR) over the last 6 years, with Q3 2025 value amounting to 125.69%.

  • Pharming's EBITDA Margin rose 1202000.0% to 125.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.04%, marking a year-over-year increase of 138900.0%. This contributed to the annual value of 2.9% for FY2024, which is 7000.0% down from last year.
  • Latest data reveals that Pharming reported EBITDA Margin of 125.69% as of Q3 2025, which was up 1202000.0% from 2.21% recorded in Q2 2025.
  • Pharming's 5-year EBITDA Margin high stood at 484.88% for Q1 2022, and its period low was 29.35% during Q1 2024.
  • Over the past 5 years, Pharming's median EBITDA Margin value was 0.49% (recorded in 2021), while the average stood at 32.48%.
  • Per our database at Business Quant, Pharming's EBITDA Margin crashed by -522000bps in 2021 and then skyrocketed by 4704600bps in 2022.
  • Over the past 5 years, Pharming's EBITDA Margin (Quarter) stood at 15.69% in 2021, then fell by -19bps to 18.68% in 2022, then soared by 64bps to 6.63% in 2023, then crashed by -40bps to 9.3% in 2024, then skyrocketed by 1451bps to 125.69% in 2025.
  • Its EBITDA Margin was 125.69% in Q3 2025, compared to 2.21% in Q2 2025 and 8.91% in Q1 2025.